Jeremiah de Leon1, David Crawford1, Zoë Moutrie1, Stacy Alvares1, Louise Hogan1, Claire Pagulayan1, Urszula Jelen1, Conrad Loo1, Jack D. Aylward2,3,1, Kieran Condon1, Nicolle Dunkerley1, Monique Y. Heinke1, Sandy Sampaio1, Kathy Simon1, Tania Twentyman1, Michael Jameson4,1
1GenesisCare, Sydney, New South Wales, Australia
2Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, The University of Manchester, Manchester, UK
3Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
4Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
Tóm tắt
AbstractIntroductionThe magnetic resonance linear accelerator (MRL) offers improved soft tissue visualization to guide daily adaptive radiotherapy treatment. This manuscript aims to report initial experience using a 1.5 T MRL in the first 6 months of operation, including training, workflows, timings and dosimetric accuracy.MethodsAll staff received training in MRI safety and MRL workflows. Initial sites chosen for treatment were stereotactic and hypofractionated prostate, thoraco‐abdomino‐pelvic metastasis, prostate bed and bladder. The Adapt To Shape (ATS) workflow was chosen to be the focus of treatment as it is the most robust solution for daily adaptive radiotherapy. A workflow was created addressing patient suitability, simulation, planning, treatment and peer review. Treatment times were recorded breaking down into the various stages of treatment.ResultsA total of 37 patients were treated and 317 fractions delivered (of which 313 were delivered using an ATS workflow) in our initial 6 months. Average treatment times over the entire period were 50 and 38 min for stereotactic and non‐stereotactic treatments respectively. Average treatment times reduced each month. The average difference between reference planned and ionization chamber measured dose was 0.0 ± 1.4%.ConclusionThe MRL was successfully established in an Australian setting. A focus on training and creating a detailed workflow from patient selection, review and treatment are paramount to establishing new treatment programmes.
